Posted on

Singapore NASDAQ Listed Precision Cleaning Systems Manufacturer And A Provider of Centralized Dishwashing And Ancillary Services, JE Cleantech Holdings Rings Closing Bell

SINGAPORE, Aug 1, 2022 - (ACN Newswire via SEAPRWire.com) - JE Cleantech Holdings Limited (Nasdaq: JCSE), (the "Company"), Singapore's leading manufacturer of precision cleaning systems and a provider of centralized dishwashing and ancillary services, recently rang the closing bell of the NASDAQ stock exchange.JE Cleantech Holdings Limited rings NASDAQ Closing BellElise Hong, CEO and Co-Founder, JE Cleantech Holdings LimitedNASDAQ Tower, New YorkJE Cleantech is a Singapore-based manufacturer of precision cleaning systems and a provider of centralized dishwashing and ancillary services in Singapore and Malaysia. Started in 1999, the company has an established local client network of long-term customers across Southeast Asia with a growing international footprint in markets such as Europe and the United States. The company also recently made its first foray into the tech hardware industry, securing its first contract to develop precision cleaning systems for a sensor products manufacturer.About JE Cleantech Holdings LimitedJE Cleantech Holdings Limited is based in Singapore and is principally engaged in (i) the sale of cleaning systems and other equipment; and (ii) the provision of centralized dishwashing and ancillary services. Through its subsidiary, JCS-Echigo Pte Ltd, the company designs, develops, manufactures, and sells cleaning systems for various industrial end-use applications primarily to customers in Singapore and Malaysia. Its cleaning systems are mainly designed for precision cleaning, with features such as particle filtration, ultrasonic or megasonic rinses with a wide range of frequencies, high pressure drying technology, high flow rate spray, and deionized water rinses, which are designed for effective removal of contaminants and to minimize particle generation and entrapment. The Company also has provided centralized dishwashing services, through its subsidiary, Hygieia Warewashing Pte Ltd, since 2013 and general cleaning services since 2015, both mainly for food and beverage establishments in Singapore. http://www.jecleantech.sg/For Media Enquiries and Investor Relations, please contact:jcse@preciouscomms.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

JE Cleantech Secures More Than US$700,000 in New Orders During the First Half of 2022, Expands Capabilities into Tech Hardware

SINGAPORE, Jul 14, 2022 - (ACN Newswire via SEAPRWire.com) - JE Cleantech Holdings Limited (Nasdaq: JCSE), (the "Company"), a Cayman Islands company whose group operations are based in Singapore, today announced the receipt of a new order by its subsidiary, JCS-Echigo Pte Ltd, from a major customer in Singapore. Under this new order, the group will design, develop and manufacture a new precision cleaning system under the customer's specified requirements. The new order is valued at approximately US$700,000 and represents an expansion of JE Cleantech Holding's presence in the tech hardware industry. The new customer designs and manufactures sensor products. The new customer is part of the international group that serves clients worldwide. With the new precision cleaning system by JCSE, the new customer will be able to deliver better services to its customers.JE Cleantech Holdings has experience in manufacturing precision cleaning systems for a wide range of sectors - past orders include cleaning and equipment manufacturing for hard disk drives, semiconductors, biomedical, food and beverage, and industrial electronics companies. As a leading homegrown industrial manufacturer with a long and proven track record, the entry into this new sector demonstrates JE Cleantech's ability to apply its expertise to different sectors to scale and support its growth.The precision-cleaning equipment manufacturing market in Singapore is estimated to reach an estimated S$143.0 million by 2025, marking a CAGR of 9.0 percent over the forecasted period. It also reflects an optimistic market outlook for the precision cleaning industry. The group also provides cleaning equipment and centralized washing services for food courts, hawker centers, restaurants, cookhouses, eldercare homes, and an inflight catering service provider. The Company has also maintained a healthy balance sheet through the height of the pandemic, the new partnership is the first step in a strong recovery for Singapore's industrial sector and positive prospects for the years to come. In the near term, JE Cleantech intends to double production capacity. The Company is looking to further expand its product portfolio and increase the size of its R&D and engineering team. Longer-term, the Company aims to become the preferred choice for all industrial precision cleaning needs in Singapore.About JE Cleantech Holdings LimitedJE Cleantech Holdings Limited is based in Singapore and is principally engaged in (i) the sale of cleaning systems and other equipment; and (ii) the provision of centralized dishwashing and ancillary services. Through its subsidiary, JCS-Echigo Pte Ltd, the company designs, develops, manufactures, and sells cleaning systems for various industrial end-use applications primarily to customers in Singapore and Malaysia. Its cleaning systems are mainly designed for precision cleaning, with features such as particle filtration, ultrasonic or megasonic rinses with a wide range of frequencies, high pressure drying technology, high flow rate spray, and deionized water rinses, which are designed for effective removal of contaminants and to minimize particle generation and entrapment. The Company also has provided centralized dishwashing services, through its subsidiary, Hygieia Warewashing Pte Ltd, since 2013 and general cleaning services since 2015, both mainly for food and beverage establishments in Singapore. http://www.jecleantech.sg/For Media Enquiries and Investor Relations, please contact:jcse@preciouscomms.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

CerbACT Asia Holds Ribbon Cutting to Celebrate New Immuno-oncology Centre of Excellence

HONG KONG, Oct 7, 2021 - (ACN Newswire via SEAPRWire.com) - ACT Genomics Holdings Co. Ltd. ("ACT Genomics" or "the Group") announced today that CerbACT Asia (Taipei, Taiwan), a Cerba Research and ACT Genomics joint venture, had unveiled its new purpose-built facility to empower precision medicine for better patient outcomes. The opening ceremony of CerbACT AsiaThe opening ceremony held on the 30th September 2021, was attended by distinguished guests virtually and in-person, marking the start of operations and expansion of the precision medicine offer in Asia. Deep scientific expertise from both sides of the joint venture supports new growth areas for biotech and pharma clients globally to drive better patient outcomes across all phases of clinical trials. State-of-the-art technologies and instrumentation strengthen capabilities and services offered to clients on a truly global scale, including: - Cutting-edge flow cytometry technologies- Exploratory and next-generation IHC histopathology services- PBMC and cell isolations from blood and soft tissues Mario Papillon, CEO of Cerba Research, comments, "Our expansion with ACT Genomics validates our innovative history as a company. With this new centre of immuno-oncology excellence in Taiwan, supported by a larger scientific team and new instrumentation, we will continue to lead and change the shape of clinical drug development while helping our customers capitalize on cutting edge technologies and experienced scientists, for a powerful advantage in the oncology space."In the opening ceremony, Professor Pan-Chyr Yang, Academician of Academia Sinica and former President of National Taiwan University, remarks, "We believe that CerbACT Asia can be a game player in the next generation precision health, which will benefit and take care of patients in Asia and all over the world." In the opening ceremony, Dr Johnsee Lee, Chairman of Precision Medicine & Molecular Diagnostic Industry Association of Taiwan, says, "A very important laboratory and a very important milestone.... An important collaboration between Asia and Europe.""Everyone here at CerbACT Asia is fully committed to provide high-quality results to our clients and hope to improve patient outcomes through precision medicine," says Dr George Wei, Managing Director of CerbACT Asia."We are excited to create a union with Cerba Research. Together, we offer a broader range of top-notch technologies and services in Asia. The formation of CerbACT Asia echoes our firm dedication to the well-being of cancer patients, keen commitment to society, and unequivocal embrace of precision medicine," concludes Dr Hua Chien Chen, CEO of ACT Genomics.About CerbACT AsiaCerbACT Asia is an Immuno-Oncology Centre of Excellence that empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research and clinical development strategies. It is enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC / cell isolations, while functioning as a Central Laboratory in the APAC region. Working with biotech, pharma, government, and non-government organizations, our team is ready to turn precision medicine into action.About Cerba ResearchCerba Research is a strategic provider of diagnostic solutions and supports drug development by leveraging patient data and scientific insight to optimize R&D and commercialization globally. Providing early phase research, clinical development through central laboratory and diagnostic testing, assay and biomarker development and validation - through our global network of specialty laboratories. We partner with government agencies, non-government organizations, and pharma and biotech organizations to change the shape of clinical development and advance healthcare.Cerba Research is part of Cerba HealthCare, a leading player in medical diagnosis. About ACT GenomicsACT Genomics is an innovation-driven cancer solution provider with offices in Taipei, Hong Kong, Singapore, Tokyo and Wales (UK). With our Next-Generation Sequencing (NGS) technology, CAP-accredited laboratories, experienced bioinformatics team, and proprietary AI algorithms, we provide optimal cancer treatment planning, immunotherapy evaluation, cancer relapse & drug resistance monitoring, as well as cancer risk assessment services to medical professionals. Together, we "Turn Genomics into Action".For further information, please contact:Strategic Financial Relations LimitedAngelus Lau Tel: (852) 2864 4805 Email: angelus.lau@sprg.com.hk Karen Kwan Tel: (852) 2114 4171 Email: karen.kwan@sprg.com.hk Doris Ho Tel: (852) 2114 4916 Email: doris.ho@sprg.com.hk Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Daiwa Securities Upgrades Rating of Parent Company of Precision Tsugami (1651.HK) to “Outperform”

HONG KONG, Sep 6, 2021 - (ACN Newswire via SEAPRWire.com) - Daiwa Securities, in its recently published research report, has upgraded the rating for the parent company of Precision Tsugami (China) Corporation Limited ("Precision Tsugami" or the "Company", stock code: 1651), which is the largest foreign-owned CNC high-precision machine tool manufacturer in the PRC . The "Outperform" rating was given to the firm as Daiwa Securities was particularly optimistic about Precision Tsugami's strong business foundation in the PRC, and the higher-than-expected number of orders received in July. In the report, Daiwa Securities noted that Precision Tsugami brought a new plant on stream in Anhui Province, the PRC, in March 2021, thus increasing total production capacity by just above 15%. The ability to supply the needed volume of products by the deadlines demanded by customers is particularly important in the PRC. The Group commands a lofty share of the local market for small- and mid-size sliding headstock automatic lathes (60-70% by its estimate). Leveraging its strong profile, the Company has established close relations with a number of local area suppliers and appears to be well positioned when it comes to securing the parts, materials and workforce needed for business activities. At this juncture, the procurement difficulties have not had a major impact on the Company's production. In view of the higher-than-expected number of orders in July, Daiwa Securities raised its revenue forecast for the parent company of Precision Tsugami. The forecasted revenue and operating profit for FY21 are 100.5 billion yen (HK$7.084 billion) and 20.5 billion yen (HK$1.445 billion), respectively, and 107 billion yen (HK$7.542 billion) and 21.8 billion yen (HK$1.537 billion) in FY22, respectively. Daiwa Securities believes that orders will remain at a high level. In the first quarter of FY22, Precision Tsugami accounted for 70% of the parent company's revenue.Since its establishment, Precision Tsugami has been committed to developing, manufacturing and selling modern CNC machine tools. Currently, it manufactures various high-end precision CNC machine tools such as automatic lathes, turret machines, machining centres and grinding machines that are used in diverse industries, spanning automotive parts, smart phones and 5G communications to automation, medical equipment and construction machinery. The Company is the largest overseas production base of Tsugami Japan. In addition to selling its products in the PRC, the Company also exports to Japan, South Korea, Taiwan, Europe, the United States and other markets.About Precision Tsugami (China) Corporation LimitedThe Group is an established foreign-owned CNC high-precision machine tool manufacturer in the PRC which primarily engages in the manufacture and sales of a wide range of CNC high precision machine tools under the TSUGAMI brands. The Group has been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 25 September 2017. The Group's CNC high-precision machine tools can be broadly classified into four major product categories, namely, precision lathes, precision machining centres, precision grinding machines and precision thread and form rolling machines. The Group offers CNC high-precision machine tools that are of standardised design and specifications to its customers and is able to provide machine tool solutions to them and make various specifications and/or customisations to CNC high-precision machine tools. According to Frost & Sullivan, in terms of revenue in 2017, the Group ranked third in the CNC high-precision machine tool industry in the PRC and was the largest foreign-owned CNC high-precision machine tool manufacturer in the PRC. The Group also ranked first in the PRC precision automatic lathe market in terms of revenue in 2017, with a market share of approximately 49.8%. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

NEC Joins the CONNECT Landmark Public-private Initiative for Precision Cancer Medicine

TOKYO, Mar 8, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (TSE: 6701) today announced that it has joined a landmark public-private initiative, the Norwegian Precision Cancer Medicine Implementation Consortium (CONNECT), a collaboration between 22 key public and private partners for promoting precision cancer medicine. CONNECT is one of four interconnected initiatives in Norway that will ensure infrastructure and collaboration on diagnostics, clinical trials, implementation of advanced precision medicine and use of health data, e.g., for health economics analysis. By joining the network of this Norwegian consortium and leveraging advanced real-world data, NEC hopes to reinforce and accelerate its personalized cancer immunotherapy activities. While more than 30,000 Norwegians are diagnosed with cancer every year, and the incidence is still increasing, more precise treatments can save lives. CONNECT is a new initiative aiming to ensure that precision medicine reaches the patients. "A serious cancer disease is an existential challenge for the individual. Cancer research gives hope. The pharmaceutical industry and the public health sector, clinicians and executive authorities, have to collaborate to offer new treatments, balancing the latest research with hospital operations," says Asmund Flobak, Oncologist at St Olav's Hospital, Trondheim University Hospital. The new initiative is a direct response to Health Minister Bent Hoie's political guidance to accelerate the implementation of precision medicine for Norwegian patients. It also responds to the Health Minister's ambition to increase research and collaboration between public and private actors, including hospitals, other public stakeholders, the Norwegian Cancer Society, and the pharmaceutical industry.CONNECT Founding Partners:- Akershus universitetssykehus HF- Helse Bergen HF- Helse Stavanger HF- St. Olavs hospital HF- Universitetssykehuset Nord-Norge HF- Oslo Universitetssykehus med Kreftregisteret og OUH Comprehensive Cancer Center- Folkehelseinstituttet- Oslo Cancer Cluster SA- Kreftforeningen- Legemiddelindustrien- Roche Norge AS- Bristol-Myers Squibb Norway Ltd NUF- Novartis Norge AS- Merck AB NUF- Takeda AS- Amgen AB Norge NUF- AstraZeneca AS- AbbVie AS- Bayer AS- PubGene AS- Pfizer Norge AS- NEC CorporationFor more information:- Oslo Cancer Cluster: bit.ly/3qzl40N- NEC's Drug Discovery Business: https://www.nec.com/en/global/solutions/healthtech/About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More